SCHEMBL1674634

SCHEMBL1674634

COC(=O)c1nnc2ccc3nc(Cl)c(-c4ccccc4)nc3n12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 4/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 2/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
PLA2G2A P14555 1/20 0.37
GABRA1 P14867 2/20 0.37
GABRG2 P18507 2/20 0.37
GABRB3 P28472 2/20 0.37
GABRA5 P31644 2/20 0.37
GABRA3 P34903 2/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
GABRA4 P48169 1/20 0.37
GABRE P78334 1/20 0.37
GABRA6 Q16445 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12806846 0.88 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDPLA2G2AGABRA1
SCHEMBL1674646 0.84 PDE2A (0.44) ALDH1A1KDM4EPKMHPGDGLA
SCHEMBL1674600 0.78 KDM4E (0.50) ALDH1A1KDM4EPKMHPGDGLA
SCHEMBL1674484 0.75 TYMS (0.41) ALDH1A1KDM4EPKMGAASMN1; SMN2
SCHEMBL1674618 0.74 TGFBR1 (0.37) ALDH1A1KDM4EHPGDGAASMN1; SMN2
SCHEMBL1674474 0.74 KDM4E (0.45) ALDH1A1KDM4EPKMHPGDGLA
SCHEMBL1674593 0.73 KDM4E (0.41) ALDH1A1KDM4EPKMHPGDGLA
SCHEMBL1459040 0.70 ALDH1A1 (0.57) ALDH1A1KDM4EPKMHPGDGAA
SCHEMBL9960774 0.70 ALDH1A1 (0.57) ALDH1A1KDM4EPKMHPGDGAA
SCHEMBL11781121 0.69 THRB (0.57) ALDH1A1KDM4EHPGDGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2303269-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2014-07-30 EP disclosed
US-8207169-B2 Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D MSD K.K. (JP) 2012-06-26 US disclosed
US-8207169-B2 Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D MSD K.K. (JP) 2012-06-26 US disclosed
US-8207169-B2 Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D MSD K.K. (JP) 2012-06-26 US disclosed
US-20110092511-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2011-04-21 US disclosed
US-20110092511-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092511-A1 INHIBITORS OF AKT ACTIVITY AKT1S1, AKT1, PIK3CA ALDH1A1 4132/4885KDM4E 1224/4885PKM 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.